- Conditions
- Healthy Volunteer
- Interventions
- Mosliciguat, 14C mosliciguat, Dry Powder Inhaler
- Drug · Device
- Lead sponsor
- Pulmovant, Inc.
- Industry
- Eligibility
- 18 Years to 50 Years · Male only
- Enrollment
- 8 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–4
of 4
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Pulmonary Hypertension, Interstitial Lung Disease, Vascular Diseases, Cardiovascular Diseases, Fibrosis
- Interventions
- Mosliciguat, Placebo, Dry Powder Inhaler
- Drug · Device
- Lead sponsor
- Pulmovant, Inc.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 376 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 3
- States / cities
- Kissimmee, Florida • Louisville, Kentucky • Bend, Oregon
- Conditions
- Pulmonary Hypertension, Interstitial Lung Disease (ILD), Lung Diseases, Vascular Diseases, Cardiovascular Diseases, Fibrosis
- Interventions
- inhaled mosliciguat, Dry Powder Inhaler
- Drug · Device
- Lead sponsor
- Pulmovant, Inc.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 13
- States / cities
- Santa Barbara, California • Torrance, California • Kissimmee, Florida + 10 more
- Conditions
- Pulmonary Hypertension, Interstitial Lung Disease, Lung Diseases, Vascular Diseases, Cardiovascular Diseases, Fibrosis
- Interventions
- Mosliciguat, Dry Powder Inhaler, Placebo
- Drug · Device
- Lead sponsor
- Pulmovant, Inc.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 135 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • Los Angeles, California • Sacramento, California + 20 more